Patents by Inventor Youzhi Li

Youzhi Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210121439
    Abstract: Provided is use of tectorigenin in the preparation of a medicament for treatment of chicken necrotic enteritis. Using tectorigenin for treating chicken necrotic enteritis can significantly reduce the degree of pathological changes in the intestinal tract of chickens with necrotic enteritis, and has a good therapeutic effect on chicken necrotic enteritis caused by Clostridium perfringens.
    Type: Application
    Filed: May 14, 2019
    Publication date: April 29, 2021
    Applicants: SHANDONG GUANGYUAN PHARMACEUTICAL SCI. & TECH.CO., LTD, SHANDONG JINZHUJI PHARMACEUTICAL CO., LTD
    Inventors: Yunfeng HOU, Xuming DENG, Chuanjin ZHANG, Shui LIU, Jianfeng WANG, Youzhi LI, Jing NIE, Junping ZHU, Guizhen WANG, Yong ZHANG, Xiaoye FAN, Jian ZHANG, Tingting WANG, Yonglin ZHOU, Qianghua LV
  • Patent number: 10927376
    Abstract: The present invention provides asymmetrical duplex RNA molecules that are capable of effecting sequence-specific gene silencing. The RNA molecule comprises a first strand and a second strand. The first strand is longer than the second strand. The RNA molecule comprises a double-stranded region formed by the first strand and the second strand, and two ends independently selected from the group consisting of 5?-overhang, 3?-overhang, and blunt end. The RNA molecules of the present invention can be used as research tools and/or therapeutics.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: February 23, 2021
    Assignee: 1GLOBE HEALTH INSTITUTE LLC
    Inventors: Chiang Jia Li, Xiangao Sun, Harry Rogoff, Youzhi Li
  • Publication number: 20210024482
    Abstract: The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such corn pounds with specific administration regimen; to methods of targeting cancer stem cells by inhibiting Stat3 pathway; to methods of using novel compounds in the treatment of conditions or disorders in a mammal related to aberrant Stat3 pathway activity; and to processes for preparing such compounds and intermediates thereof and to the pharmaceutical compositions of relevant compounds, and to the specific methods of administration of these compounds.
    Type: Application
    Filed: May 15, 2020
    Publication date: January 28, 2021
    Applicant: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Chiang Jia Li, Harry Rogoff, Youzhi Li, Jifeng Liu, Wei Li
  • Publication number: 20200397740
    Abstract: The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.
    Type: Application
    Filed: April 7, 2020
    Publication date: December 24, 2020
    Applicant: Sumitomo Dainnipon Pharma Oncology. Inc.
    Inventors: Chiang Jia Li, Wei Li, David Leggett, Youzhi Li, David Kerstein, Matthew Hitron
  • Patent number: 10646464
    Abstract: Methods for treating advanced thymoma and thymic carcinoma in a subject comprising administering and kits comprising at least one paclitaxel compound and at least one compound of formula (I) (2-acetylnaphtho[2,3-b]furan-4,9-dione) as disclosed herein.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: May 12, 2020
    Assignee: Boston Biomedical, Inc.
    Inventors: Chiang Jia Li, Youzhi Li, Wei Li, Matthew Hitron, Yuan Gao
  • Publication number: 20200071696
    Abstract: The present invention provides asymmetrical duplex RNA molecules that are capable of effecting sequence-specific gene silencing. The RNA molecule comprises a first strand and a second strand. The first strand is longer than the second strand. The RNA molecule comprises a double-stranded region formed by the first strand and the second strand, and two ends independently selected from the group consisting of 5?-overhang, 3?-overhang, and blunt end. The RNA molecules of the present invention can be used as research tools and/or therapeutics.
    Type: Application
    Filed: March 11, 2019
    Publication date: March 5, 2020
    Inventors: Chiang Jia LI, Xiangao SUN, Harry ROGOFF, Youzhi LI
  • Publication number: 20200063128
    Abstract: The present invention provides asymmetrical duplex RNA molecules that are capable of effecting sequence-specific gene silencing. The RNA molecule comprises a first strand and a second strand. The first strand is longer than the second strand. The RNA molecule comprises a double-stranded region formed by the first strand and the second strand, and two ends independently selected from the group consisting of 5?-overhang, 3?-overhang, and blunt end. The RNA molecules of the present invention can be used as research tools and/or therapeutics.
    Type: Application
    Filed: February 20, 2019
    Publication date: February 27, 2020
    Inventors: Chiang Jia LI, Xiangao SUN, Harry ROGOFF, Youzhi LI
  • Patent number: 10568526
    Abstract: A combined physiological sensor and methods for detecting one or more physiological characteristics of a subject are provided. The combined sensor (e.g., a forehead sensor) may be used to detect and/or calculate at least one of a pulse blood oxygen saturation level, a regional blood oxygen saturation level, a respiration rate, blood pressure, an electrical physiological signal (EPS), a pulse transit time (PTT), body temperature associated with the subject, a depth of consciousness (DOC) measurement, any other suitable physiological parameter, and any suitable combination thereof. The combined sensor may include a variety of individual sensors, such as electrodes, optical detectors, optical emitters, temperature sensors, and/or other suitable sensors. The sensors may be advantageously positioned in accordance with a number of different geometries.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: February 25, 2020
    Assignee: Covidien LP
    Inventors: Edward M. McKenna, Bo Chen, Youzhi Li, Paul Stanley Addison
  • Publication number: 20200039948
    Abstract: The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such compounds with specific administration regimen; to methods of targeting cancer stem cells by inhibiting Stat3 pathway; to methods of using novel compounds in the treatment of conditions or disorders in a mammal related to aberrant Stat3 pathway activity; and to processes for preparing such compounds and intermediates thereof, and to the pharmaceutical compositions of relevant compounds, and to the specific methods of administration of these compounds.
    Type: Application
    Filed: December 31, 2018
    Publication date: February 6, 2020
    Inventors: Chiang Jia Li, Harry Rogoff, Youzhi Li, Jifeng Liu, Wei Li
  • Patent number: 10543189
    Abstract: The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: January 28, 2020
    Assignee: Boston Biomedical, Inc.
    Inventors: Chiang Jia Li, Wei Li, David Leggett, Youzhi Li, David Kerstein, Matthew Hitron
  • Publication number: 20190388382
    Abstract: The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.
    Type: Application
    Filed: August 16, 2019
    Publication date: December 26, 2019
    Inventors: Chiang Jia Li, Wei Li, David Leggett, Youzhi Li, David Kerstein, Matthew Hitron
  • Publication number: 20190262319
    Abstract: The invention provides thiazole-substituted indolin-2-ones as inhibitors of cancer stem cell pathway kinases (CSCPK) and related kinases, and methods of using these compounds, to treat subjects in need thereof.
    Type: Application
    Filed: October 25, 2018
    Publication date: August 29, 2019
    Inventors: Chiang Jia Li, Youzhi Li
  • Publication number: 20190248781
    Abstract: The present invention relates to novel thiazole-substituted indolin-2-ones as inhibitors of CSCPK and related kinases; to methods of inhibiting cancer stem cells by using a kinase inhibitor; to pharmaceutical compositions containing such compounds; and to methods of using such compounds in the treatment of a protein kinase related disorder in a mammal; and to processes of making such compounds and intermediates thereof.
    Type: Application
    Filed: November 14, 2018
    Publication date: August 15, 2019
    Inventors: Chiang Jia Li, Ji-Feng Liu, Youzhi Li, Wei Li, Harry Rogoff
  • Patent number: 10377731
    Abstract: The present invention relates to the composition and methods of use of Stat3 pathway inhibitors or cancer stem cell inhibitors in combination treatment of cancer.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: August 13, 2019
    Assignee: Boston Biomedical, Inc.
    Inventors: Chiang Jia Li, Keith Mikule, Youzhi Li
  • Publication number: 20190231735
    Abstract: Methods comprising administration of, and kits comprising, at least one compound of formula (I) FOLFIRI, and optionally at least one angiogenesis inhibitor.
    Type: Application
    Filed: March 25, 2019
    Publication date: August 1, 2019
    Inventors: Chiang Jia Li, Wei Li, Youzhi Li, Laura Borodyansky, Yuan Gao, David P. Kerstein
  • Publication number: 20190135773
    Abstract: The present invention relates to the composition and methods of use of Stat3 pathway inhibitors or cancer stem cell inhibitors in combination treatment of cancer.
    Type: Application
    Filed: January 14, 2019
    Publication date: May 9, 2019
    Inventors: Chiang Jia Li, Keith Mikule, Youzhi Li
  • Patent number: 10266821
    Abstract: The present invention provides asymmetrical duplex RNA molecules that are capable of effecting sequence-specific gene silencing. The RNA molecule comprises a first strand and a second strand. The first strand is longer than the second strand. The RNA molecule comprises a double-stranded region formed by the first strand and the second strand, and two ends independently selected from the group consisting of 5?-overhang, 3?-overhang, and blunt end. The RNA molecules of the present invention can be used as research tools and/or therapeutics.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: April 23, 2019
    Assignee: 1GLOBE HEALTH INSTITUTE LLC
    Inventors: Chiang Jia Li, Xiangao Sun, Harry Rogoff, Youzhi Li
  • Publication number: 20180353111
    Abstract: Described herein are methods and apparatus monitoring a patient. In one example, a sensor that is configured to detect physiological changes in a patient is driven at a first current level and a subsequent sensor voltage is measured. Thereafter the current is varied to a second current level, and a next sensor voltage is measured. A next sensor voltage is projected based on the sensor voltage and the subsequent sensor voltage, and a third current level is identified that could produce the next sensor voltage. The third current level is compared to a threshold, and an alarm is produced in response thereto. The apparatus further includes elements in the sensor that facilitate the method.
    Type: Application
    Filed: June 7, 2018
    Publication date: December 13, 2018
    Inventors: William Kip Buxton, Robert W. Eikel, Youzhi Li, Dan Lisogurski, Christopher Joseph Meehan
  • Publication number: 20180333385
    Abstract: Methods for treating advanced thymoma and thymic carcinoma in a subject comprising administering and kits comprising at least one paclitaxel compound and at least one compound of formula (I) (2-acetylnaphtho[2,3-b]furan-4,9-dione) as disclosed herein.
    Type: Application
    Filed: May 16, 2018
    Publication date: November 22, 2018
    Inventors: Chiang Jia Li, Youzhi Li, Wei Li, Matthew Hitron, Yuan Gao
  • Publication number: 20180250261
    Abstract: Methods comprising administering and kits comprising at least one compound of formula A: (A) prodrugs, derivatives, pharmaceutically acceptable salts of any of the foregoing, and solvates of any of the foregoing, and at least one compound of formula B: (B) prodrugs, derivatives, pharmaceutically acceptable salts of any of the foregoing, and solvates of any of the foregoing.
    Type: Application
    Filed: April 26, 2016
    Publication date: September 6, 2018
    Applicant: BOSTON BIOMEDICAL, INC.
    Inventors: Chiang J. LI, Youzhi LI, Harry ROGOFF, Yuan GAO, Janet HUANG